Renalytix PLC Presentation at 2021 Wells Fargo Healthcare Conf.
September 03 2021 - 2:00AM
RNS Non-Regulatory
TIDMRENX
Renalytix PLC
03 September 2021
Renalytix plc
("Renalytix" or the "Company")
Renalytix to present at the 2021 Wells Fargo Virtual Healthcare
Conference
NEW YORK and SALT LAKE CITY, September 3, 2021 -- Renalytix plc
(LSE: RENX) (NASDAQ: RNLX) announces that the Company will be
presenting at the upcoming 2021 Wells Fargo Virtual Healthcare
Conference.
Renalytix's management is scheduled to participate in a fireside
chat Friday, September 10 at 2:40 p.m. EDT. Interested parties may
access a live and archived webcast of the presentation on the
"Investors" section of the company website at
investors.renalytix.com .
For further information, please contact:
Renalytix plc www.renalytix.com
James McCullough, CEO Via Walbrook PR
Stifel (Nominated Adviser, Joint Broker) Tel: 020 7710 7600
Alex Price / Nicholas Moore
Investec Bank plc (Joint Broker) Tel: 020 7597 4000
Gary Clarence / Daniel Adams
Walbrook PR Limited Tel: 020 7933 8780 or renalytix@walbrookpr.com
Paul McManus / Lianne Cawthorne Mob: 07980 541 893 / 07584 391 303
About Kidney Disease
Kidney disease is now recognized as a public health epidemic
affecting over 850 million people globally. The Centers for Disease
Control and Prevention (CDC) estimates that 15% of US adults, or 37
million people, currently have chronic kidney disease (CKD).
Further, the CDC reports that 9 out of 10 adults with CKD do not
know they have it and one out of two people with very low kidney
function who are not on dialysis do not know they have CKD.(1)
Kidney disease is referred to as a "silent killer" because it often
has no symptoms and can go undetected until a very advanced stage.
Each year, kidney disease kills more people than breast and
prostate cancer. Every day, 13 patients in the United States die
while waiting for a kidney transplant.
(1) https://www.cdc.gov/kidneydisease/publications-resources/2019-national-facts.html
About KidneyIntelX(TM)
KidneyIntelX, is a first-of-kind, platform that employs a
proprietary artificial intelligence-enabled algorithm to combine
diverse data inputs, including validated blood-based biomarkers,
inherited genetics, and personalized patient data from electronic
health record, or EHR, systems, to generate a unique patient risk
score. This patient risk score enables prediction of progressive
kidney function decline in chronic kidney disease, or CKD, allowing
physicians and healthcare systems to optimize the allocation of
treatments and clinical resources to patients at highest risk.
About Renalytix
Renalytix (LSE: RENX) (NASDAQ: RNLX) is a developer of
artificial intelligence-enabled clinical in vitro diagnostic
solutions for kidney disease, one of the most common and costly
chronic medical conditions globally. The Company's lead product is
KidneyIntelX, which has been granted Breakthrough Designation by
the U.S. Food and Drug Administration and which is designed to help
make significant improvements in kidney disease prognosis,
transplant management, clinical care, patient stratification for
drug clinical trials, and drug target discovery (visit
www.kidneyintelx.com ). For more information, visit
www.renalytix.com .
Forward Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995, as amended. Examples of these forward-looking statements
include statements concerning: the potential benefits, including
economic savings, of KidneyIntelX, the potential for KidneyIntelX
to receive regulatory approval from the FDA, the commercial
prospects of KidneyIntelX, if approved, including whether
KidneyIntelX will be successfully adopted by physicians and
distributed and marketed, our expectations regarding reimbursement
decisions and the ability of KidneyIntelX to curtail costs of
chronic and end-stage kidney disease, optimize care delivery and
improve patient outcomes. Words such as "anticipates," "believes,"
"estimates," "expects," "intends," "plans," "seeks," and similar
expressions are intended to identify forward-looking statements. We
may not actually achieve the plans and objectives disclosed in the
forward-looking statements, and you should not place undue reliance
on our forward-looking statements. Any forward-looking statements
are based on management's current views and assumptions and involve
risks and uncertainties that could cause actual results,
performance or events to differ materially from those expressed or
implied in such statements. These risks and uncertainties include,
among others: that KidneyIntelX is based on novel artificial
intelligence technologies that are rapidly evolving and potential
acceptance, utility and clinical practice remains uncertain; we
have only recently commercially launched KidneyIntelX; and risks
relating to the impact on our business of the COVID-19 pandemic or
similar public health crises. These and other risks are described
more fully in our filings with the Securities and Exchange
Commission (SEC), including the "Risk Factors" section of our
annual report on Form 20-F filed with the SEC on October 28, 2020,
and other filings we make with the SEC from time to time. All
information in this press release is as of the date of the release,
and we undertake no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events, or otherwise, except as required by law.
Sources
1
https://www.cdc.gov/kidneydisease/publications-resources/2019-national-facts.html
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRADKBBNDBKBFCK
(END) Dow Jones Newswires
September 03, 2021 02:00 ET (06:00 GMT)
Renalytix (LSE:RENX)
Historical Stock Chart
From Apr 2024 to May 2024
Renalytix (LSE:RENX)
Historical Stock Chart
From May 2023 to May 2024